1. McColl KE. Clinical practice.
Helicobacter pylori infection. N Engl J Med 2010;362:1597–1604.
3. Jung HK, Kang SJ, Lee YC, et al. Evidence-based guidelines for the treatment of
Helicobacter pylori infection in Korea: 2020 revised edition. Korean J Helicobacter Up Gastrointest Res 2020;20:261–287.
4. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of
Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016;43:514–533.
5. Rokkas T, Gisbert JP, Malfertheiner P, et al. Comparative effectiveness of multiple different first-line treatment regimens for
Helicobacter pylori infection: a network meta-analysis. Gastroenterology 2021;161:495–507; e4.
6. Song JG, Lee SW, Park JY, et al. Trend in the eradication rates of Helicobacter pylori infection in the last 11 years. Korean J Med 2009;76:303–310.
9. Shin WG, Lee SW, Baik GH, et al. Eradication rates of
Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use: nationwide survey. Helicobacter 2016;21:266–278.
10. Zamani M, Alizadeh-Tabari S, Zamani V, Shokri-Shirvani J, Derakhshan MH. Worldwide and regional efficacy estimates of first-line
Helicobacter pylori treatments: a systematic review and network meta-analysis. J Clin Gastroenterol 2022;56:114–124.
11. Lee JH, Ahn JY, Choi KD, et al. Nationwide antibiotic resistance mapping of
Helicobacter pylori in Korea: a prospective multicenter study. Helicobacter 2019;24:e12592.
13. Oh MK, Choi WS, Lee YB, Chung HR, Kang GH, Kim JS. The effect of smoking on eradication of Helicobacter pylori. J Korean Acad Fam Med 1999;20:991–999.
14. Korean H. pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J Gastroenterol 1998;32:275–289.
15. Graham DY, Lu H, Yamaoka Y. A report card to grade
Helicobacter pylori therapy. Helicobacter 2007;12:275–278.
16. Kim N, Kim JJ, Choe YH, et al. Diagnosis and treatment guidelines for
Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009;54:269–278.
17. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of
Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol 2013;62:3–26.
18. Lee JY, Kim W, Gwak GY, et al. Reinfection rate and clinical manifestation of Helicobacter pylori-positive peptic ulcer disease after triple therapy containing clarithromycin. Korean J Gastroenterol 2002;39:93–100.
19. Kim BW, Choi MG, Choi H, et al. Pooled analysis of antibiotic therapy for Helicobacter pylori eradication in Korea. Korean J Gastroenterol 1999;34:42–49.
22. Cho DK, Park SY, Kee WJ, et al. The trend of eradication rate of
Helicobacter pylori infection and clinical factors that affect the eradication of first-line therapy. Korean J Gastroenterology 2010;55:368–375.
23. Na HS, Hong SJ, Yoon HJ, et al. Eradication rate of first-line and second-line therapy for
Helicobacter pylori infection, and reinfection rate after successful eradication. Korean J Gastroenterol 2007;50:170–175.
24. Paek NY, Lim YJ, Lee JH, Kang JH, Park JB, Lee JH. Recent eradication rates of first-line triple regimens for H. pylori infection. Korean J Gastrointest Endosc 2010;41:5–9.
25. Yoon JH, Baik GH, Sohn KM, et al. Trends in the eradication rates of
Helicobacter pylori infection for eleven years. World J Gastroenterol 2012;18:6628–6634.
26. Tshibangu-Kabamba E, Yamaoka Y.
Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021;18:613–629.
27. Lee JH, Sung IK, Kim JH, et al. Impact of clarithromycin resistance on the outcome of standard triple Helicobacter pylori eradication therapy. Korean J Helicobacter Up Gastrointest Res 2010;10:14–20.
28. Lee JY, Kim N, Kim MS, et al. Factors affecting first-line triple therapy of
Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 2014;59:1235–1243.
30. Gong EJ, Ahn JY. Antimicrobial resistance of
Helicobacter pylori isolates in Korea. Korean J Helicobacter Up Gastrointest Res 2018;18:82–88.
32. An B, Moon BS, Kim H, et al. Antibiotic resistance in
Helicobacter pylori strains and its effect on
H. pylori eradication rates in a single center in Korea. Ann Lab Med 2013;33:415–419.
33. Lee JY, Kim N, Nam RH, Choi SI, Lee JW, Lee DH. Primary and secondary antibiotic resistance of
Helicobacter pylori in Korea from 2003 to 2018. Helicobacter 2019;24:e12660.
34. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of
Helicobacter pylori infection-the maastricht v/florence consensus report. Gut 2017;66:6–30.
35. Jung YS, Lee SH, Park CS, et al. Trends in the eradication rates of
Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years. Korean J Gastroenterol 2014;63:82–89.
36. Kim JY, Kim NY, Kim SJ, et al. Regional difference of antibiotic resistance of
Helicobacter pylori strains in Korea. Korean J Gastroenterol 2011;57:221–229.
37. Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of
Helicobacter pylori. Helicobacter 2022;27:e12860.
38. Kang JM, Kim N, Lee DH, et al. Effect of the CYP2C19 polymorphism on the eradication rate of
Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol 2008;23(8 Pt 1): 1287–1291.
39. Kim J, Kim YJ, Chung WC. Proton pump inhibitor switching strategy after failure of standard triple therapy for
Helicobacter pylori infection. Korean J Helicobacter Up Gastrointest Res 2020;20:146–152.
40. Baena JM, López C, Hidalgo A, et al. Relation between alcohol consumption and the success of
Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol 2002;14:291–296.